Spectral AI, Inc. (NASDAQ: MDAI) announced De Novo clearance for its DeepView Burn diagnostic in a May 26th press release. As a result, we increase our probability of success for DeepView burn from 75% to 100%, which raises our valuation to $6.25 per share. Management’s attention will shift from regulatory matters to commercial and clinical trial efforts. FDA clearance also entitles the company to access another $6.5 million in debt financing from Avenue Capital, which will require a parallel equity raise of $7.0 million.
Following the clearance, Spectral’s first priority is to hire a Chief Commercial Officer (CCO). Based on our conversations with management, we believe that they have identified a candidate and will appoint them to their role before the end of the second quarter. The new CCO will benefit from a list of prospects that have experience with the device and have recognized its value. The commercialization effort will be funded by the Biomedical Advanced Research and Development Authority (BARDA) award. The initial award will pay for up to 30 DeepView devices at deserving centers following FDA clearance. Management is optimistic that several units may be deployed in Europe, Australia, and/or the Middle East this year.
For domestic deployments, the company is planning to begin the commercial effort in earnest after the summer. The timing acknowledges the academic year at teaching hospitals and summer vacations, which may limit the number of available decision makers. This approach suggests that the first domestic deployments may take place in the fourth quarter. While some devices already sit in inventory, manufacturing can be completed quickly. Spectral plans to manufacture devices when they have a placement confirmed, which will allow for just in time inventory. Waiting to build inventory will offer units that have the latest software, battery, and algorithm. The device manufacturer is located just a few miles from Spectral AI’s headquarters in Dallas, Texas, which enables management to have close and frequent contact with the manufacturing operations.
BARDA’s grant funds support continued development work for DeepView, including efforts to conduct health economic and outcome research studies for deployed units. The work will support the broader clinical adoption of the DeepView system and emphasize real-world outcomes. Management has finalized the design of the outcomes study with BARDA. It anticipates approximately 286 patients in the study across at least 12 sites. We expect further information on the study during the second quarter 2026 conference call, coming in August.
Valuation
We recently caught up with Spectral AI management to refine our estimates for 2026 and 2027, taking into account anticipated deployments, the nature of reimbursement for deployed devices (outright purchase vs. lease), and additional expenses tied to the upcoming outcomes study. We also increased our probability of regulatory success to 100% from 75% following the FDA clearance of the DeepView burn diagnostic. The results from our model adjustments generate an updated valuation of $6.25 per share.
Milestones
- Vincent Capone elevated to CEO – February 2026
- Award of $31.7 million of BARDA funding – March 2026
- Acceptance of Small Business Innovator Award at the Texas Innovation Conference – April 2026
- Attendance at the 2026 American Burn Association Annual Meeting – April 2026
- Fully functional prototype of handheld SnapShot delivered – May 2026
- Annual Meeting of Stockholders – May 29th, 2026
- Stockholder meeting results and business update – June 1st, 2026
- Development of health economic and outcome study – 2026
- Launch of DeepView in US Burn Centers – 2H:26
- Launch of health economic and outcome study – 4Q:26
- Decision on contract award for SnapShot handheld device by MTEC – December 2026
- Launch of DeepView in US Emergency Departments (Burn) – 2026/2027
- DeepView SnapShot Launch for Military Use – 2027
Summary
We hear echoes of Spectral AI’s Executive Chairman, Dr. J. Michael DiMaio’s maxim “Finance, Focus and Finish” as the FDA clears the DeepView burn device. Now that the “Finish” portion of that objective is achieved, we anticipate that the company will apply the motto to the next stage of its growth as it commercializes the device and expands into new studies and indications. The “Finance” portion of the effort moves front and center as Spectral is now eligible to draw another $6.5 million from its facility with Avenue Capital in parallel with an equity raise. Spectral’s ”Focus” will shift to commercialization, where there appears to be many geographies of interest. The company will use its BARDA grant to fund deployments in the United States and take advantage of relationships overseas to deploy units in Europe, Australia, and the Middle East.
Following the clearance of DeepView, we increase our valuation to $6.25 per share, reflecting a 100% probability of regulatory success. This allows Spectral to conduct its health economic and outcome research to support the broader clinical adoption of the DeepView System.
John Vandermosten, Zacks CSR, 1st June 2026
Read the full report…
Spectral AI (MDAI): Zacks – DeepView FDA Clearance Fires Up Our Valuation
by u/_DoubleBubbler_ in DoubleBubbler
